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ABSTRACT
Introduction: Recurrent or persistent low back pain is
common after back surgery but is typically not well
controlled. Previous randomised controlled trials on
non-acute pain after back surgery were flawed. In this
article, the design and protocol of a randomised
controlled trial to treat pain and improve function after
back surgery are described.
Methods and analysis: This study is a pilot
randomised, active-controlled, assessor-blinded trial.
Patients with recurring or persistent low back pain after
back surgery, defined as a visual analogue scale value
of ≥50 mm, with or without leg pain, will be randomly
assigned to an electroacupuncture-plus-usual-care
group or to a usual-care-only group. Patients assigned
to both groups will have usual care management,
including physical therapy and patient education, twice
a week during a 4-week treatment period that would
begin at randomisation. Patients assigned to the
electroacupuncture-plus-usual-care group will also
have electroacupuncture twice a week during the
4-week treatment period. The primary outcome will be
measured with the 100 mm pain visual analogue scale
of low back pain by a blinded evaluator. Secondary
outcomes will be measured with the EuroQol
5-Dimension and the Oswestry Disability Index. The
primary and secondary outcomes will be measured at
4 and 8 weeks after treatment.
Ethics and dissemination: Written informed
consent will be obtained from all participants. This
study was approved by the Institutional Review Board
(IRB) of Pusan National University Korean Hospital in
September 2013 (IRB approval number 2013012).
The study findings will be published in peer-reviewed
journals and presented at national and international
conferences.
Trial registration number: This trial was registered
with the US National Institutes of Health Clinical Trials
Registry: NCT01966250.
INTRODUCTION
Billions of dollars have been spent worldwide
in the past few years on lumbar spine surgery
to treat chronic low back pain (LBP), and
thousands of studies have been devoted to the
subject.1 Lumbar spine surgery is becoming
more common, and there is a wide range of
surgical procedures.2 Complications can be
acute or can occur later after surgery, and they
can lead to worsening or to lack of resolution
of the original symptoms.3 Approximately,
40% of patients who undergo lumbar spine
surgery continue to report signiﬁcant pain
after the surgery.4 Pain management is a very
important element of patient care because
pain is the most common complication of
back surgery.5 6 Various opioid analgesics,
including morphine, hydromorphine and
meperidine, have been used for postoperative
pain management.7 However, opioids are
frequently observed to have unwanted side
effects, such as nausea and vomiting.8
Therefore, there is a need for safe and effect-
ive pain management after back surgery.
Numerous studies have shown that acupunc-
ture is generally safe9 10 and cost-effective11
compared with routine care.12 13
Electroacupuncture (EA) is also commonly
Strengths and limitations of this study
▪ This trial is designed to be a feasible, compara-
tive effectiveness trial design that is similar to
common clinical situations.
▪ Individualised acupuncture points according to
patients’ symptoms during the delivery of acu-
puncture treatment reflect the real clinical prac-
tice of acupuncture.
▪ We expect that this pilot study will provide the
clinical basis and information that is required to
assess the feasibility of a future large-scale trial.
▪ Blinding the practitioner will not be done in this trial
because it is impossible to blind acupuncturists.
▪ The size of the study sample limits the power of
the observations.
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used for pain management.14–16 The primary goal of EA
treatment after back surgery is pain reduction. There has
been a systematic review of current evidence concerning
the effectiveness of acupuncture for relieving acute post-
operative pain after back surgery.17 However, there have
been only a few clinical trials18 19 that evaluated the effect-
iveness of EA for non-acute postoperative pain after back
surgery, and the quality of these studies is too low to draw
any meaningful conclusions.
In Korea, because of cultural inﬂuence, many potential
study participants who are between 19 and 70 years old
have already had experience with acupuncture. This
makes it difﬁcult to implement participant blinding and
practitioner blinding given the nature of acupuncture.20 21
We therefore propose to conduct a pilot feasibility study
to establish an appropriate sample size before conducting
a conﬁrmative, pragmatic, comparative randomised con-
trolled trial (RCT) to demonstrate the effectiveness of EA
in combination with usual care (UC) compared with UC
alone for controlling non-acute pain and function at
≥3 weeks22 after the back surgery. The study will adhere to
STRICTA23 and CONSORT24 guidelines.
Aims
The primary purpose of this study is to explore whether
EA in combination with UC can provide beneﬁts to
patients with non-acute pain and dysfunction after back
surgery. It is also a pilot feasibility study that is designed
to estimate the appropriate sample size for a future con-
ﬁrmative, pragmatic, comparative RCT that would verify
the effectiveness of EA in combination with UC (drug
treatment and physical therapy) compared with UC
alone in relieving non-acute pain and dysfunction after
back surgery. The dependent variables are pain relief,
enhancing disease-related functional status and
improved quality of life. We also aim to conduct a cost-
effectiveness analysis and a qualitative study with the
pilot data, but these results will be reported separately.
METHODS AND ANALYSIS
Study design
This study is a randomised, active-controlled, assessor-
blinded pilot trial with two parallel arms. The trial will
be conducted in the Pusan National University Korean
Medicine Hospital (PNUKH) in Yangsan, Korea. This
study protocol is registered with ClinicalTrials.gov
(Identiﬁer: NCT01966250, 11-Oct-2013).
Participants
Inclusion criteria
Patients whose LBP recurred or persisted after back
surgery, with or without leg pain.
Patients whose pain persisted for at least 3 weeks (non-
acute) after back surgery and who require intermittent
medical treatment, such as medication, injection or
physical therapy.
Patients with LBP, deﬁned as a visual analogue scale
(VAS) value of ≥50 mm.
Patients who are between 19 and 70 years of age.
Patients who agreed to participate voluntarily in this
study and signed written informed consent forms.
Exclusion criteria
Patients who have been diagnosed with a serious disease
that can cause LBP, including cancer, vertebral fracture,
spinal infection, inﬂammatory spondylitis and cauda
equina compression.
Patients with a progressive neurological deﬁcit or with
severe neurological symptoms.
Patients whose pain is not caused by spinal or soft
tissue diseases, such as ankylosing spondylitis, ﬁbromyal-
gia, rheumatoid arthritis or gout.
Patients with a chronic disease that could inﬂuence
the treatment effects or results (eg, severe cardiovascular
disease, diabetic neuropathy, dementia or epilepsy).
Patients for whom EA might be inappropriate or
unsafe (eg, because of haemorrhagic disease, clotting
disorders, a history of having received anticoagulant
therapy within the preceding 3 weeks, severe diabetes
with a risk of infection or severe cardiovascular disease).
Patients who are currently pregnant or planning to
become pregnant.
Patients with psychiatric diseases.
Patients who are participating in another clinical trial.
Patients who are unable to sign a written informed
consent form.
Patients who are judged to be inappropriate for the
clinical study by the researchers, such as those who are
unable to read and write Korean.
Recruitment
Patients will be recruited by advertisements on hospital
websites, bulletin boards and in local newspapers. If hos-
pital patients are interested in participating, they will be
asked to answer screening questions to determine their
eligibility. If they are eligible, they will be guided
through the written informed consent process. After
written consent is obtained, a study researcher will
administer the baseline questionnaire. Patients who have
been determined on the basis of the selection and
exclusion criteria to be suitable for the clinical trial will
be assigned randomly on a second visit to either the
UC-plus-EA group or the UC-alone group, with a 1:1
ratio. After randomisation, a clinical research coordin-
ator (CRC) will schedule the treatment procedure. The
ﬁrst participant was enrolled in 29 October 2013.
Randomisation
Before the ﬁrst treatment session, a statistical expert will
assign patients to one of the two groups by use of a
central telephone randomisation process according to a
computer-generated randomisation sequence that uses
SPSS V.19.0 (IBM Co, Armonk, New York, USA).
Randomisation will be conducted by a trial coordinator
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who will have no contact with the patients. The CRC will
obtain the codes for the trial (A or B) from a central
telephone and inform the practitioner. The practitioner
will then use these codes to assign patients to one of the
two groups and to deliver the appropriate treatment.
The National Clinical Research Centre at the PNUKH
will store the random number. The allocation sequence
will be concealed from the researcher who is responsible
for enrolling, treating or assessing patients (ﬁgure 1).
Blinding
It is not possible to blind patients or practitioners in our
trial because of the nature of EA and because there is
no placebo. However, there is protection from detection
bias because treatment and assessment will be con-
ducted independently, and the practitioners will not be
involved in outcome assessment.25 The assessors will
always perform outcome assessments in a separate room
and will always be blinded to treatment assignment.
Unblinding of assessors should be performed only when
exceptional circumstances occur as knowledge of the
actual treatment is absolutely essential for further man-
agement of the patient (eg, serious adverse event).
Education of practitioners for standardisation
The licensed Korean medicine doctors (KMDs) who will
be involved in this trial as practitioners or assessors have
all been certiﬁed by the Korean Ministry of Health and
Welfare, have at least 3 years of clinical experience, and
will have taken a course to ensure that they adhere
strictly to the study protocol and are familiar with
administering the study treatments. All participating
KMDs underwent intensive and customised training for
a full understanding of the EA procedure, including
such details as acupuncture points, depth and
manipulation. All study protocols and details, including
the recording method for the case report form and
outcome assessment methods, were additionally standar-
dised among the assessors by means of 10 h of training
on the standard operating procedure.
Interventions
Patients who are randomised to both arms will have UC
management during the 4-week treatment period, which
begins at randomisation. It is assumed in this study that
UC includes drug therapy, physiotherapy or an educa-
tional programme about LBP.22 Conventional medicinal
drug treatment or therapies (eg, pain medication, injec-
tion or physiotherapy, but not surgical treatment) that
are related to treating LBP after back surgery will be
allowed, and they will be monitored. Physiotherapy and
an educational programme about back pain will be per-
formed twice a week for 4 weeks by licensed KMDs.
Interferential current therapy (ICT, OG Giken Co,
Okayama, Japan) will last 15 min, and therapy with a hot
(or ice) pack will last 10 min. The education programme
will be conducted through the brochure, including the
physiology, pathology and epidemiology of pain after
back surgery. Additionally, KMDs will present suitable
postures and exercises for LBP in 15 min face-to-face
education sessions.
Patients who are randomised to the UC-plus-EA group
will have EA treatment in addition to the UC. In the
UC-plus-EA group, the acupuncture point prescriptions
used will be personalised to each patient and at the dis-
cretion of the practitioner. Differentiating the acupunc-
ture point is an important part of traditional Korean
medical theory and of creating the actual clinical situ-
ation, so it was used to select acupuncture points accord-
ing to patients’ symptoms. EA treatment procedures
Figure 1 Flow chart showing
the steps in participant
recruitment, treatment and
analysis.
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were designed to reﬂect the feasibility afforded by the
actual clinical setting by a consensus of ﬁve experts on
acupuncture and the spine. EA treatment will be per-
formed by licensed KMDs using disposable stainless steel
needles that are 0.25 mm in diameter and 0.40 mm in
length (Dongbang Acupuncture Inc, Seongnam,
Korea). Electric stimulation will be applied with an
ES-160 electronic stimulator (ITO co. LTD, Japan) twice
a week for 4 weeks. Stimulation will be applied with
biphasic waveform current, which is a compressional
wave that combines an interrupted wave and a continu-
ous wave, in triangular form, at a frequency of 50 Hz.26
Acupuncture points will include Jia-ji (Ex-B2, L3-L5;
bilateral) as required points and other reasonable points
can be chosen by the practitioner as accessory points.
Between 6 and 15 access points will be used by the physi-
cians according to the individual clinical features of
each patient. Electric stimulation will be given through
alligator clips, connected to Jia-ji (Ex-B2, L3/L5; bilat-
eral). Each EA session will last 15 min. Patients in both
groups will have had a total of eight treatment sessions
during 4 weeks.
The rationale of the lack of a placebo/sham
intervention group
The primary purpose of this study is to explore whether
EA combined with UC can provide beneﬁts to patients
with non-acute pain after back surgery. Currently, sham
or placebo EA is used to assess the efﬁcacy of the spe-
ciﬁc component of the EA while reducing any possible
inﬂuence from clinical contexts and other treatment-
related processes.27 28 However, with the purpose of
pragmatic, comparative effectiveness RCT of future trial,
we decided not to employ a placebo/sham EA as a
control group.
OUTCOME ASSESSMENT
At the initial screening visit, a CRC will ask patients to
complete a questionnaire regarding their sociodemo-
graphic characteristics, including age, gender, height,
weight and vital signs. A CRC or KMD with more than
2 years of clinical experience will record the outcomes in
a separate room according to the standardised operating
procedure without knowing to which group the patients
have been assigned. Before the start of treatment at each
visit, patients will be assessed to record the outcomes of
the previous treatments. Any disease history or adverse
events will be recorded and will be used to decide if a par-
ticipant should continue in the trial. Follow-up assess-
ments will be performed at 4 and 8 weeks after the
4-week treatment period (table 1 and ﬁgure 1).
Primary outcome measurements
Back pain intensity will be assessed using the 100 mm
pain VAS, on which 0 indicates the absence of pain and
100 indicates unbearable pain.29 30 The VAS was selected
as a primary outcome measurement of the clinical sever-
ity of patients’ pain after back surgery. Using the
100 mm pain VAS, the participant will be asked to check
his or her degree of back pain for the previous 3 days.
Back pain will be measured at baseline (assessment 1),
prior to each of the eight treatment sessions (assess-
ments 2 through 9), and during the two follow-up visits
(assessments 10 and 11). The primary end point is
assessment 10, which marks the end of the eight active
treatment sessions.
Secondary outcome measurements
The Oswestry Disability Index (ODI) is one of two sec-
ondary outcome measurements that will be used. The
ODI assesses back pain-related disability.31 It contains 10
questions about daily life, including measures of pain
intensity, personal care, lifting, walking, sitting, standing,
sleeping, social life and travelling. Each question is rated
on a scale of 0–5, with a higher score indicating a more
severe pain-related disability. The validated Korean
version of the ODI32 will be administered before treat-
ment on the ﬁrst, fourth and eighth treatment sessions
(assessments 2, 5 and 9) and during each of the two
follow-up sessions (assessments 10 and 11).
Responder, deﬁned as a participant with 50% or more
pain relief using a 100 mm VAS for pain intensity, versus
non-responder (under 50% pain relief) will be assessed
at eighth treatment session (assessment 9) and the two
follow-up sessions (assessments 10 and 11). The
Table 1 Schedule for data collection and outcome measurement
Baseline Active treatment Follow-up
Measures Week 0
1st
week
2nd
week
3rd
week
4th
week 8th week* 12th week*
Sociodemographic characteristics √
Back pain history √
Physical examination √
Visual analogue scale for back pain √ √ √ √ √ √ √ √ √ √ √
Oswestry Disability Index √ √ √ √ √
EuroQol 5-Dimensions √ √ √ √ √
Adverse events √ √ √ √ √ √ √ √ √ √
*8, 12-weeks indicates 4 and 8 weeks, respectively, after 4 weeks of electroacupuncture treatment.
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EuroQol 5-Dimension (EQ-5D) will also be used as a sec-
ondary outcome measurement. The quality of life of
patients with back pain will be assessed using the vali-
dated Korean version of the EQ-5D.33 34 The EQ-5D
includes generic questions about quality of life as it
relates to personal health. The EQ-5D consists of ﬁve
dimensions that pertain to mobility (mobility), self-care
(self-care), daily activities (usual activities), pain and dis-
comfort (pain), and anxiety and depression (anxiety/
depression). Each dimension is scored on a scale of 1–3,
with a lower score indicating a better state of participant
health. The EQ-5D will be administered before treat-
ment on the ﬁrst, fourth and eighth treatment sessions
(assessments 2, 5 and 9) and during each of the two
follow-up sessions (assessments 10 and 11).
Data management
Data and safety monitoring will be conducted periodic-
ally during the study and at least once a year thereafter.
Only speciﬁc research assistants will have access to the
ﬁnal trial data set. The research assistants will consist of
two independent researchers (one in biomedical statis-
tics, one in clinical expert of Korean medicine) who will
not be involved in the trial. Monitors will oversee study
protocol compliance, informed consent documents,
overall progress of the trial, participant recruitment,
data quality and timeliness, performance of the interven-
tion and all ﬁelds and processes of the trial. If any
important protocol modiﬁcations exist, we will resubmit
amended protocol to Institutional Review Board (IRB).
Important protocol modiﬁcations will be announced to
relevant parties (eg, investigators, IRB, trial participants,
trial registries and sponsor). Audit will be carried out by
the Korean Food & Drug Administration that adheres to
its rule. Interim analysis will not be applied because we
expect this small pilot trial to be a minimal risk of harm
to be associated with EA and UC. All study-related infor-
mation will be stored securely at the study site. All par-
ticipant information will be stored for 10 years in locked
ﬁle cabinets in areas with limited access.
Sample size
Although our study is a pilot trial, we attempted to approxi-
mate a sample size that would be suitable for a future,
large, pragmatic, multicentred, comparative effectiveness
RCT. We also attempted to estimate more exactly the power
of a future trial. The sample size for the future clinical
study was estimated by comparing the mean difference in
the VAS for LBP between the experimental and control
groups in the pilot study. As there was no same trial with
our design of RCT, we estimated the sample size on the
basis of other similar previous study.35–37 The mean differ-
ence in the pain VAS for LBP between the experimental
and control groups was 20 mm suggested as clinically
important change.38 39 The SD between the two groups
was estimated to be 19, based on other published
results.18 19 40 When a two-tailed test with a test power of
80% and a signiﬁcance level of 5% (α error) was applied to
the following formula, the number of participants required
for each group was found to be 16. Considering a dropout
rate of 20% and a 1:1 allocation ratio, the total sample size
was calculated to be 20. On the other hands, in previous
pilot trials which were performed without calculating the
number of sample size to enforce the number of samples
of 20.28 35–37 41 42
Sample size n
2(Za=2 þ Z1b)2d2
(mt  mc)2
n=the number of participants required in each group
μt–μc=20
δ=19
Zα/2=Z0.05/2=1.96
Z1–β=Z0.8=0.84
Statistical methods and analysis
The statistical analysis will be performed according to
the principle of intention-to-treat (ITT) analysis and per-
protocol (PP) analysis. In the case of ITT analysis, we
will apply the last-observation-carried-forward rule for
missing data. In parallel, PP analysis will be conducted
without patients who dropped out of the clinical trials
for any reason. Additionally, the subgroups of patients
with pain after back surgery will be evaluated and ana-
lysed (subgroup analysis) for exploring potential future
research. Subgroup analysis will be conducted according
to the type of surgery (ie, fusion, decompression or disc-
ectomy), surgically involved spine(s) (which level(s)
was/were and how many levels were involved) and post-
operative period (subacute: 3 weeks or more to
3 months vs chronic: more than 3 months) for exploring
the feasibility of future trial. The signiﬁcance of the dif-
ferences in the various data in each group will be ana-
lysed with a paired t test, and the signiﬁcance of the
differences between groups will be analysed with an
independent t test. An analysis of covariance will be
used to analyse and adjust baseline characteristics if
there are statistically signiﬁcant differences and there is
a possibility of covariance of baseline characteristics.
Non-parametric statistical tests (a Wilcoxon signed-rank
test or the Wilcoxon rank-sum test) will be used if the
data are not normally distributed. A χ2 test or a Fisher’s
exact test will be performed to analyse categorical data,
such as responses/responders that are recorded and
described as frequencies (%). All statistical analyses will
be conducted with SPSS statistical software (IBM Co,
Armonk, New York, USA) for Windows, V.19.0, by a stat-
istician. The signiﬁcance level will be set at 5%. Sample
size estimation was conducted by the free program of
G*Power V.3.1.7 (Franz Faul, Uniesität Kiel, Germany).
Safety
All possible adverse events that could affect patients will be
monitored and reported for every trial by the participating
researchers. Every expected or unexpected adverse event
related to this study will be recorded and monitored until
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it is resolved. And those who suffer harm from trial partici-
pation can be given medical treatment for compensation.
The research team will report any differences in the safety
of the experimental and control groups.
Ethics and dissemination
In conformity with the Declaration of Helsinki,43 all par-
ticipants will be recruited to participate voluntarily, and
they will sign a written informed consent form.
Participation can be ended at any time during the clin-
ical trial if a participant refuses to continue or if there is
signiﬁcant clinical deterioration, as determined by the
KMDs. The study ﬁndings will be disseminated in peer-
reviewed journals and presented at national and inter-
national conferences.
DISCUSSION
EA is commonly used for pain management after
surgery.44–47 There has been a systematic review summaris-
ing the current evidence concerning the effectiveness of
acupuncture for treating acute postoperative pain after
back surgery,17 but few clinical trials have evaluated the
effectiveness of EA for treating non-acute postoperative
pain after back surgery. We have therefore designed this
pilot RCT to guide the design of a full-scale randomised
trial. The results of our study will determine the appropri-
ate sample size for a future feasible, pragmatic, compara-
tive effectiveness RCT to evaluate the effectiveness and
cost-effectiveness of EA with UC compared with UC alone
in the treatment of non-acute pain after back surgery.
From the subgroup analysis of the type of surgery and the
surgically involved level of spine, we will explore the poten-
tial factor(s) related to the difference of effectiveness of
EA on pain and function after back surgery.
A strength of our study is that it is designed to be a
feasible, comparative effectiveness trial design that is
similar to common clinical situations. Additionally, this
clinical trial protocol was conducted to conform strictly
to the STRICTA statement23 and the CONSORT state-
ment.24 We expect that this pilot study will provide the
clinical basis and information that is required to assess
the feasibility of a future large-scale trial.
TRIAL STATUS
The trial is currently in the recruitment phase. The
results of this trial will be available in 2015.
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